Good Samuel D, Sparks Jeffrey A, Volkmann Elizabeth R
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.
Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.
Rev Colomb Reumatol. 2024 Apr;31(Suppl 1):S3-S14. doi: 10.1016/j.rcreu.2023.06.002. Epub 2023 Aug 26.
Interstitial lung disease (ILD) is a common and serious manifestation of autoimmune rheumatic diseases. While the prevalence of ILD differs among the individual autoimmune rheumatic diseases, ILD remains an important cause of morbidity and mortality in systemic sclerosis, systemic lupus erythematosus, mixed connective tissue disease, primary Sjögren's disease, rheumatoid arthritis, and idiopathic inflammatory myositis. The present review summarizes recent literature on autoimmune-associated ILD with a focus on screening and monitoring for ILD progression. Reflecting on the currently available evidence, the authors propose a guideline for monitoring for progression in patients with newly diagnosed autoimmune-associated ILD. This review also highlights clinical and biological predictors of progressive pulmonary fibrosis and describes opportunity for further study in the rapidly evolving area of rheumatology and pulmonology.
间质性肺疾病（ILD）是自身免疫性风湿性疾病常见且严重的表现形式。虽然ILD在各自身免疫性风湿性疾病中的患病率有所不同，但在系统性硬化症、系统性红斑狼疮、混合性结缔组织病、原发性干燥综合征、类风湿关节炎和特发性炎性肌病中，ILD仍然是发病和死亡的重要原因。本综述总结了近期关于自身免疫相关ILD的文献，重点关注ILD进展的筛查和监测。基于目前可得的证据，作者提出了针对新诊断的自身免疫相关ILD患者监测疾病进展的指南。本综述还强调了进行性肺纤维化的临床和生物学预测指标，并描述了在快速发展的风湿病学和肺病学领域进一步研究的机会。
